{
    "root": "34888df6-f68d-c171-e063-6294a90a7604",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "DESVENLAFAXINE",
    "value": "20250507",
    "ingredients": [
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "DESVENLAFAXINE SUCCINATE",
            "code": "ZB22ENF0XR"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "Desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (MDD)\n \n  [see\n  \n   Clinical Studies (14)].",
    "contraindications": "Recommended dose: 50 mg once daily with or without food ( 2.1 ). There was no evidence that doses greater than 50 mg per day confer any additional benefit ( 2.1 ). The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment or dosing in severe renal and end-stage renal disease patients ( 2.1 ). Discontinuation: Reduce dose gradually whenever possible ( 2.1 ). Take tablets whole; do not divide, crush, chew, or dissolve ( 2.1 ). Moderate renal impairment: Maximum dose 50 mg per day ( 2.2 ). Severe renal impairment and end-stage renal disease: Maximum dose 25 mg per day or 50 mg every other day ( 2.2 ). Moderate to severe hepatic impairment: Maximum dose 100 mg per day ( 2.3 ).",
    "warningsAndPrecautions": "Desvenlafaxine extended-release tablets are available as follows:\n                  \n                  25 mg, brown colored, round shaped convex, film coated tablet debossed with \"˄\" on one side\n                  and plain on the other side                                                                                    A41                                            \n                  NDC 72603-555-01 bottle of 30 tablets\n                  50 mg, pink colored, round shaped convex, film coated tablet debossed with \"˄\" on one side and\n                  plain on the other side                                                                                       A42\n                  NDC 72603-556-01 bottle of 30 tablets\n                  NDC 72603-556-02 bottle of 90 tablets\n                  100 mg, beige colored, round shaped convex, film coated tablet debossed with \"˄\" on one side\n                  and plain on the other side                                                                                     A43                                            \n                  NDC 72603-557-01 bottle of 90 tablets\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)\n \n  [see USP Controlled Room Temperature].\n\n \n                  \n                  Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively.",
    "adverseReactions": "Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation. Angioedema has been reported in patients treated with desvenlafaxine extended-release tablets\n  \n   [see\n   \n    Adverse Reactions (6.1)]\n  \n   .\n \n  \n                  \n                  \n                     The use of MAOIs intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets is contraindicated because of an increased risk of serotonin syndrome. The use of desvenlafaxine extended-release tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated\n  \n   [see\n   \n    Dosage and Administration (2.7)\n                        and\n  \n   \n                           Warnings and Precautions (5.2)].\n  \n   \n                     \n                     Starting desvenlafaxine extended-release tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome\n  \n   [see\n   \n    Dosage and Administration (2.8)and\n   \n    Warnings and Precautions (5.2)]."
}